Jumpcan Pharmaceutical's wholly-owned subsidiary, Jumpcan Pharmaceutical Group, recently received drug registration certificates for Pediatric Laxative Granules and Mesalazine Extended-Release Granules approved and issued by the National Medical Products Administration. Pediatric Laxative Granules is a proprietary innovative traditional Chinese medicine of Category 1.1, indicated for pediatric constipation due to food accumulation. Mesalazine Extended-Release Granules is a chemical drug of Category 3, used for the treatment of ulcerative colitis and Crohn's disease. The company is the first in China to pass the consistency evaluation for this drug. The approval of these drugs will enrich the company's product pipeline and is expected to have a positive impact on development, but sales are subject to uncertainties due to factors such as industry policies.
Hubei Jumpcan Pharmaceutical Co LtdObtained drug registration certificates for two new products, enriching pipeline.
